폐경 여성에서 3년 동안 호르몬 요법, Raloxifene, Alendronate 치료 후 골밀도의 변화 = The Effects of Three-year Hormone Therapy, Raloxifene and Alendronate on Bone Mineral Density in Postmenopausal Women

다국어 초록 (Multilingual Abstract)

Objectives: To evaluate the effects of three-year hormone therapy with raloxifene and alendronate treatment on bone mineral density (BMD) and vertebral fractures in postmenopausal Korean women. Methods: We studied 127 postmenopausal women who had visited the Department of Obstetrics and Gynecology of Inje University Sanggye Paik Hospital between January 2000 and June 2008. These patients were divided into alendronate (n=26), raloxifene (n=18), estrogen therapy (ET) (n=43), and estrogen-progesterone therapy (EPT) (n=40) groups. We measured BMD in the lumbar spine (L1-L4) and femoral neck at baseline at one, two, and three-years after treatment. Vertebral fractures were also assessed at baseline and at three years after treatment initiation. Results: The BMD of the lumber spine increased significantly in the alendronate group by 7.2, 8.8%, and 9.5% at 1, 2, and 3 years after treatment initiation, respectively. It increased by 0.8% in the EPT group at 1 year. The BMD of the femoral neck increased significantly in the alendronate group by 3.4, 5.3%, and 5.8% at 1, 2, and 3 years, respectively. It increased in the raloxifene group by 3.5% at 2 years. It increased in the EPT group by 3.6, 2.6%, and 2.4% at 1, 2, and 3 years, respectively. After 3 years of hormone therapy, women with osteopenia or osteoporosis showed a greater increase in BMD than did women with normal BMD, but not to a statistically significant degree. There were no new vertebral fractures in any of the four groups three years after treatment initiation. Conclusion: In postmenopausal women, treatment with alendronate, raloxifene, or hormone therapy increases bone mineral density in the spine and femoral neck and is helpful in preventing new vertebral fractures.